Navigation Links
Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
Date:5/31/2012

SAN DIEGO, May 31, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Jefferies 2012 Global Healthcare Conference in New York. The presentation is scheduled for Wednesday, June 6th at 9:30 a.m. EDT at the Grand Hyatt New York. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment for the Contrave cardiovascular outcomes trial which the company plans to initiate this quarter. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com

Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

WCG(858) 875-8629

(510) 703-9491


'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
7. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
8. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
9. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
10. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
11. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ... the District of New Jersey ... against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... that U.S. Patent No. 6,765,117 is both valid and ... its generic product until the expiration of that patent ...
(Date:8/29/2014)... 2014 Diseases largely eradicated in ... returning. Measles was declared eliminated in 2000, yet the ... August 15—the highest incidence in 20 years. In July, ... whooping cough a problem of "epidemic proportions." ... dying from these preventable diseases—in part because some parents ...
(Date:8/29/2014)... Research and Markets has announced ... Market 2014-2018" report to their offering. ... that results in demyelination, axonal transection, and neurodegeneration. The ... by the immune system, which targets neurons within the ... disease in which the damage of the myelin sheath ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... 9, 2011 /PRNewswire-USNewswire/ – CoMeD – On Friday, May ... filed an amendment to regulate vaccines containing mercury in ... buy, sell, manufacture, deliver, import, administer or distribute any ... or inorganic mercury per milliliter for children younger than ...
... 2011 Kinex Pharmaceuticals, LLC announced today that Dr. Allen ... decided to step aside as CEO. Dr. ... from a start-up biotechnology company with only a technology platform ... pre-IND to phase 2 developments. The recent collaboration established with ...
Cached Medicine Technology:Florida Legislature Refuses to Limit Mercury in Vaccines 2Florida Legislature Refuses to Limit Mercury in Vaccines 3The Board of Directors of Kinex Pharmaceuticals Appoints Dr. Allen Barnett as President Emeritus and Dr. Johnson Lau as Chief Executive Officer 2The Board of Directors of Kinex Pharmaceuticals Appoints Dr. Allen Barnett as President Emeritus and Dr. Johnson Lau as Chief Executive Officer 3
(Date:8/29/2014)... According to the latest review published by DailyGossip.org, this ... safely and naturally. The new method promises great efficiency in ... , Daily Gossip writes in its Flat Belly Forever ... how to eliminate the extra pounds, it will also show ... to body modeling. , The method reveals some breakthrough ...
(Date:8/29/2014)... The new review that can be read ... holistic system that will permanently eliminate the symptoms of this ... can achieve a cure in as fast as 30 to ... only about one week. , The Tinnitus Miracle review ... as mild hearing loss, pain in the ear and dizziness. ...
(Date:8/29/2014)... CO (PRWEB) August 29, 2014 Panic ... attack is the feeling of intense stress and fear, ... life of the sufferer, causing insecurity and affecting relationships. ... factors and there are many symptoms that patients can ... are among these symptoms. Overcoming panic attacks is extremely ...
(Date:8/29/2014)... Dr. Parsa Mohebi, founder of US ... practice to Parsa Mohebi Hair Restoration. Since officially launching ... of hair loss patients throughout Southern California. It even ... Los Angeles, Beverly Hills, and Orange County. These patients ... many of which Dr. Mohebi perfected through new technology ...
(Date:8/29/2014)... 29, 2014 According to a CNN ... Overdoses (8/25), a new study found that those ... have seen a significant decrease in the number of ... a ten year period, and comparing various states with ... find that there was about a 25% decrease in ...
Breaking Medicine News(10 mins):Health News:Flat Belly Forever Review Exposes the Way to Eliminate Body Fat Easily 2Health News:Tinnitus Miracle Review Reveals How to Gain Tinnitus Relief in 7 Days 2Health News:60 Second Panic Solution Review Exposes Simple Panic Attacks Remedy 2Health News:US Hair Restoration Changes Name to Parsa Mohebi Hair Restoration to Better Reflect Founder 2Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 2Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 3
... as Titan of Business & ... ... Washington DC,business community leaders achieved extraordinary fundraising success on,Saturday ... guests,to the Washington Convention Center for one of DC,s largest ...
... Park Ridge, Ill. (April 3, 2008) Choline, an essential nutrient ... 24 percent reduced risk of breast cancer, according to a ... of Health (NIH), to be published in The FASEB Journals ... body of evidence that links egg consumption to a decreased ...
... like dementia are on the rise. And, thanks to ... will be at the forefront of research dealing with ... research teams have won National Health and Medical Research ... in hospitals, transitions to residential care and ascertaining the ...
... 3, 2008 TeamStaff, Inc.,(Nasdaq: TSTF ) ... today announced that it entered into a three ... agreement with Sovereign,Business Capital ("SBC", formerly Business Alliance ... loan credit facility, SBC takes,assignment of TeamStaff,s prior ...
... Edwards,Lifesciences Corporation (NYSE: EW ), a global ... disease, today announced that,its chairman and chief executive ... trading plan under Rule 10b5-1 of the Securities ... similar plan that expired last,month., The new ...
... degree made attempt, but economic status also plays role ... that promote quitting smoking are more likely to have ... dangers of secondhand smoke have a similar effect on ... Wisconsin study. , In 2002 and 2003, researchers ...
Cached Medicine News:Health News:DC's Business Leaders Raise $3.3 Million at Annual Leukemia Ball Featuring Jay Leno 2Health News:DC's Business Leaders Raise $3.3 Million at Annual Leukemia Ball Featuring Jay Leno 3Health News:DC's Business Leaders Raise $3.3 Million at Annual Leukemia Ball Featuring Jay Leno 4Health News:Essential nutrient found in eggs reduces risk of breast cancer by 24 percent 2Health News:Essential nutrient found in eggs reduces risk of breast cancer by 24 percent 3Health News:Better care for dementia patients through new funding 2Health News:TeamStaff Announces Amended Revolving Credit Facility with Sovereign Business Capital 2Health News:TeamStaff Announces Amended Revolving Credit Facility with Sovereign Business Capital 3Health News:Edwards Lifesciences' Chairman and CEO Adopts New 10b5-1 Stock Trading Plan to Replace Recently Expired Plan 2Health News:Better-Educated Smokers More Likely to Quit After Seeing Ads 2
The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
... The Illuminated Phoroptor features lighted dials ... to perform refractions in the darkened setting ... pen light and leave the lights off ... features lighted sphere, cylinder power and cylinder ...
... The Reichert CT200 Tonometer ... the XCEL 250 and XCEL ... also compatible with other Zeiss-style ... mounted on the top of ...
Medicine Products: